Report

Trading in line with expectations

Despite macro uncertainties (eg Brexit & US/Chinese trade tensions), it is nice to hear positive news about a great British technology success story.

On Tuesday (7th) Kromek – an IP/science rich firm which develops cutting edge gamma and x-ray detectors for the multi-$bn medical imaging, homeland security and nuclear screening industries - said that it “expects to report revenue growth for the full year 2018/19 and EBITDA profit in-line with market expectations.” Implying a strong H2’19, with the Board continuing “to look to the future with confidence”.

Indeed, only 9 days ago the company secured a $2.7m expansion order - to be recognised over the next 24 months - under an existing 5 year security screening contract (now worth a minimum of $5.8m). In turn, further building the orderbook (ED est. $90m+) and improving visibility (ED est. >70% for FY20).

Although our forecasts and 35p/share valuation remain unchanged, we believe there is scope for upgrades in due course, particularly given the group’s modest FY20 EV/sales multiple of 3.6x vs peers at 5.7x.
Underlying
Kromek Group

Kromek Group is a developer of radiation detectors based on cadmium zinc telluride, providing detection and characterization capabilities within the medical imaging, nuclear detection and security screening markets. Co. designs, develops and produces x-ray and gamma-ray imaging and radiation detection products.

Provider
Equity Development
Equity Development

​Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.

Analysts
Paul Hill

Other Reports on these Companies
Other Reports from Equity Development

ResearchPool Subscriptions

Get the most out of your insights

Get in touch